- Home
- Publications
- Publication Search
- Publication Details
Title
Novel agents for diffuse large B-cell lymphoma
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 5, Pages 669-680
Publisher
Informa Healthcare
Online
2011-03-28
DOI
10.1517/13543784.2011.565745
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R).
- (2017) F. J. Hernandez-Ilizaliturri et al. JOURNAL OF CLINICAL ONCOLOGY
- MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma
- (2010) M. A. Milhollen et al. BLOOD
- Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
- (2010) Kensei Tobinai et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Pathogenesis of diffuse large B cell lymphoma
- (2010) Wing (John) C. Chan INTERNATIONAL JOURNAL OF HEMATOLOGY
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- The molecular background of aggressive B cell lymphomas as a basis for targeted therapy
- (2010) Daphne de Jong et al. JOURNAL OF PATHOLOGY
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Dissecting the role of mTOR: Lessons from mTOR inhibitors
- (2009) Ryan J.O. Dowling et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
- (2009) M. Gupta et al. BLOOD
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
- (2009) K. Dunleavy et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma
- (2009) Vincent Ribrag et al. CANCER
- SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
- (2009) Andrew Conroy et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
- (2009) O. A. O'Connor et al. CLINICAL CANCER RESEARCH
- Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
- (2009) T. A. Soucy et al. CLINICAL CANCER RESEARCH
- A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
- (2009) Alison T. Stopeck et al. LEUKEMIA & LYMPHOMA
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
- (2009) V Ramakrishnan et al. ONCOGENE
- Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
- (2008) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk
- (2008) A. Podolanczuk et al. BLOOD
- Mechanisms of proteasome inhibitor action and resistance in cancer
- (2008) David J. McConkey et al. DRUG RESISTANCE UPDATES
- Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma
- (2008) Kai Fu et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
- (2008) Wyndham H. Wilson et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now